X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6395) 6395
Book Review (1564) 1564
Publication (632) 632
Newspaper Article (152) 152
Book / eBook (106) 106
Newsletter (74) 74
Book Chapter (59) 59
Conference Proceeding (21) 21
Magazine Article (6) 6
Dissertation (4) 4
Report (4) 4
Transcript (4) 4
Data Set (1) 1
Presentation (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5629) 5629
humans (3996) 3996
animals (3541) 3541
mice (2146) 2146
immunology (2098) 2098
immunoglobulins (1984) 1984
female (1669) 1669
immunoglobulin g (1261) 1261
male (1245) 1245
proteins (1204) 1204
antibodies (1200) 1200
antigens (920) 920
monoclonal antibodies (833) 833
health aspects (749) 749
immunotherapy (730) 730
analysis (714) 714
research (678) 678
immunoglobulin g - immunology (659) 659
medicine (659) 659
research article (641) 641
pharmacology & pharmacy (638) 638
multidisciplinary sciences (615) 615
mice, inbred balb c (612) 612
cancer (531) 531
medicine, research & experimental (523) 523
vaccines (523) 523
expression (521) 521
immunization (520) 520
adult (518) 518
middle aged (512) 512
abridged index medicus (503) 503
science (496) 496
enzyme-linked immunosorbent assay (486) 486
inflammation (483) 483
in-vivo (456) 456
monoclonal-antibody (451) 451
lymphocytes (448) 448
antibodies, monoclonal - immunology (441) 441
disease models, animal (439) 439
immune response (434) 434
antibodies, monoclonal - therapeutic use (430) 430
cytokines (428) 428
mice, inbred c57bl (425) 425
infections (424) 424
care and treatment (412) 412
oncology (410) 410
rats (407) 407
medical research (397) 397
monoclonal-antibodies (388) 388
biochemistry & molecular biology (383) 383
therapy (382) 382
disease (380) 380
biotechnology & applied microbiology (379) 379
t cells (375) 375
immune system (372) 372
infectious diseases (360) 360
biology (357) 357
article (356) 356
dendritic cells (355) 355
immunity (352) 352
rodents (349) 349
viral antibodies (348) 348
hematology (342) 342
physiological aspects (342) 342
allergy (337) 337
immunoglobulin g - metabolism (336) 336
treatment outcome (327) 327
binding (323) 323
cell biology (323) 323
aged (319) 319
antibody (316) 316
tumors (316) 316
vaccination (316) 316
immunoglobulin g - blood (312) 312
gene expression (310) 310
peptides (308) 308
cells (307) 307
cytotoxicity (307) 307
fc receptors (306) 306
t-lymphocytes - immunology (304) 304
flow cytometry (300) 300
viruses (299) 299
intravenous immunoglobulin (293) 293
immunoglobulin e (289) 289
cell line, tumor (287) 287
protein binding (287) 287
amino acid sequence (286) 286
biochemistry (286) 286
microbiology (286) 286
biology and life sciences (283) 283
immunogenicity (283) 283
autoimmunity (279) 279
infection (279) 279
receptor (279) 279
lymphocytes t (278) 278
clinical trials (276) 276
studies (276) 276
cell line (275) 275
immunoglobulin (272) 272
medicine and health sciences (269) 269
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (84) 84
UofT at Scarborough - Stacks (5) 5
UofT at Mississauga - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Online Resources - Online (3) 3
UTL at Downsview - May be requested (3) 3
Engineering & Comp. Sci. - Stacks (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6711) 6711
French (28) 28
German (12) 12
Russian (7) 7
Spanish (6) 6
Japanese (5) 5
Chinese (3) 3
Polish (2) 2
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science, ISSN 0036-8075, 4/2008, Volume 320, Issue 5874, pp. 373 - 376
It is well established that high doses of monomeric immunoglobulin G (IgG) purified from pooled human plasma [intravenous immunoglobulin (IVIG)] confer... 
Fc receptors | Polysaccharides | Immunoglobulins | Antiinflammatories | Lectins | Antibodies | Cytotoxicity | Recapitulation theory | Idiopathic thrombocytopenic purpura | Reports | Post hoc | OLIGOSACCHARIDES | SPECIFICITY | PROTECTION | MULTIDISCIPLINARY SCIENCES | SIALYLATION | RECEPTOR | GLYCOSYLATION | IMMUNOGLOBULIN-G | AUTOIMMUNE-DISEASE | BINDING | SIALYLTRANSFERASE | Recombinant Proteins - therapeutic use | Arthritis, Experimental - drug therapy | Immunoglobulin Fc Fragments - metabolism | Humans | Receptors, Fc - metabolism | Immunoglobulins, Intravenous - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Immunoglobulin Fc Fragments - administration & dosage | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Polysaccharides - chemistry | Immunoglobulin Fc Fragments - therapeutic use | Autoimmune Diseases - drug therapy | Immunoglobulin G - chemistry | Mice, Inbred C57BL | Immunoglobulin G - therapeutic use | Recombinant Proteins - chemistry | Immunoglobulin Fc Fragments - chemistry | Glycosylation | Immunoglobulin G - administration & dosage | N-Acetylneuraminic Acid - chemistry | Galactose - chemistry | Animals | Immunoglobulins, Intravenous - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Mice, Inbred NOD | Immunoglobulins, Intravenous - chemistry | Mice | Carbohydrate Conformation | Immunoglobulin G - metabolism | Influence | Anti-inflammatory drugs | Properties | Recombinant molecules | Immunoglobulin G | Biochemistry | Immunology | Drug therapy | Autoimmune diseases | Immune system | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 03/2012, Volume 119, Issue 13, pp. 3031 - 3037
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 06/2015, Volume 13, Issue 6, pp. 967 - 977
Prophylactic factor replacement, which prevents hemarthroses and thereby reduces the musculoskeletal disease burden in children with hemophilia A, requires... 
coagulation factor | hemophilia A | recombinant fusion proteins | VIII | children | prophylaxis | Children | Coagulation factor VIII | Recombinant fusion proteins | Hemophilia A | Prophylaxis | Recombinant Fusion Proteins - immunology | Factor VIII - immunology | Hemarthrosis - diagnosis | Age Factors | Recombinant Fusion Proteins - adverse effects | Factor VIII - pharmacokinetics | Humans | Child, Preschool | Half-Life | Male | Immunoglobulin Fc Fragments - administration & dosage | North America | Hemarthrosis - blood | Immunoglobulin Fc Fragments - immunology | China | Coagulants - administration & dosage | Factor VIII - adverse effects | Female | Hemophilia A - prevention & control | Coagulants - pharmacokinetics | Hemophilia A - diagnosis | Child | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Severity of Illness Index | Drug Administration Schedule | Europe | Risk Factors | Treatment Outcome | Hemophilia A - blood | Hemarthrosis - drug therapy | Recombinant Fusion Proteins - pharmacokinetics | Factor VIII - administration & dosage | South Africa | Infusions, Intravenous | Australia | Coagulants - adverse effects | Coagulants - immunology | Hemarthrosis - prevention & control | Hemophilia A - drug therapy | Antibodies, Neutralizing - blood | Prevention | Proteins | Care and treatment | Blood coagulation factor VIII | Hemophilia | Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 05/2011, Volume 123, Issue 17, pp. 1891 - 1899
Background-Blocking of glycoprotein VI-dependent pathways by interfering in vascular collagen sites is commonly seen as an attractive target for an... 
stroke | platelet aggregation inhibitors | platelet adhesion | glycoprotein VI | platelet aggregation | CARDIAC & CARDIOVASCULAR SYSTEMS | FAB FRAGMENT | THROMBUS FORMATION | ACUTE CORONARY SYNDROME | ADHESION | CLOPIDOGREL | IN-VIVO | PERIPHERAL VASCULAR DISEASE | SOLUBLE GPVI | MICE | HEMATOLOGY | ANTITHROMBOTIC PROTECTION | EXPRESSION | Injections, Intravenous | Cricetulus | Recombinant Fusion Proteins - adverse effects | Humans | Male | Immunoglobulin Fc Fragments - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Platelet Aggregation Inhibitors - administration & dosage | Platelet Membrane Glycoproteins - administration & dosage | Adult | Platelet Membrane Glycoproteins - adverse effects | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | CHO Cells | Platelet Aggregation Inhibitors - adverse effects | Hemostasis - drug effects | Platelet Membrane Glycoproteins - pharmacokinetics | Cricetinae | Glycoproteins - administration & dosage | Collagen - administration & dosage | Animals | Platelet Count | Recombinant Fusion Proteins - pharmacokinetics | Aggregation | Safety and security measures | Blood platelets | Hemostasis | Patient outcomes | Atherosclerosis | Dosage and administration | Research | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2159 - 2167
OBJECTIVE To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The... 
GLYCEMIC CONTROL | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | ANALOG LIRAGLUTIDE | OPEN-LABEL | LY2189265 | TREATED PATIENTS | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Thiazolidinediones - administration & dosage | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Venoms - adverse effects | Hypoglycemia - drug therapy | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Safety and security measures | Dosage and administration | Metformin | Comparative analysis | Exenatide | Clinical trials | Hemoglobin | Diabetes | Product safety | Drug dosages | Placebo effect | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9951, pp. 1349 - 1357
Summary Background Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | EFFICACY | PHYSICAL-ACTIVITIES | SAFETY | PARALLEL-GROUP | EXENATIDE | ANALOG LIRAGLUTIDE | GATEKEEPING PROCEDURES | DAILY LIVING QUESTIONNAIRE | PEPTIDE-1 RECEPTOR AGONISTS | Metformin - therapeutic use | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Hypoglycemic Agents - administration & dosage | Fasting - blood | Female | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Treatment Outcome | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Analysis of Variance | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Type 2 diabetes | Usage | Research | Comparative analysis | Drug therapy | Clinical trials | Enzymes | Blood pressure | Diabetes | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2168 - 2176
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2149 - 2158
OBJECTIVE To compare the efficacy and safety of two doses of once-weekly dulaglutide, a glucagon-like peptide 1 receptor agonist, to sitagliptin in... 
METFORMIN | GLYCEMIC CONTROL | PLACEBO | GLP-1 | GLUCAGON-LIKE PEPTIDE-1 | RECEPTOR AGONISTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | ANALOG LIRAGLUTIDE | OPEN-LABEL | INHIBITOR SITAGLIPTIN | Glycated Hemoglobin A - analysis | Triazoles - administration & dosage | Triazoles - adverse effects | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Immunoglobulin Fc Fragments - administration & dosage | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Double-Blind Method | Treatment Outcome | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Pyrazines - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Sitagliptin | Care and treatment | Dosage and administration | Safety and security measures | Comparative analysis | Clinical trials | Hemoglobin | Glycosylation | Diabetes | Product safety | Placebo effect | Index Medicus | Psychosocial Research | Nutrition | Education | Clinical Care
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 11/2014, Volume 12, Issue 11, pp. 1788 - 1800
BackgroundRoutine prophylaxis with replacement factorVIII (FVIII) - the standard of care for severe hemophiliaA - often requires frequent intravenous infusions... 
Drug | Administration schedule | Pharmacokinetics | Recombinant fusion proteins | Hemophilia A | Factor VIII | SEVERE HEMOPHILIA-A | SAFETY | PROLONGED ACTIVITY | CARE | drug | factorVIII | PROPHYLACTIC TREATMENT | recombinant fusion proteins | BLOOD-GROUP | ON-DEMAND | pharmacokinetics | PERIPHERAL VASCULAR DISEASE | administration schedule | hemophiliaA | COAGULATION-FACTOR VIII | HEMATOLOGY | PRACTICE PATTERNS | Recombinant Fusion Proteins - adverse effects | Factor VIII - pharmacokinetics | Humans | Half-Life | Male | Hemorrhage - prevention & control | Immunoglobulin Fc Fragments - administration & dosage | Young Adult | Time Factors | Computer Simulation | Coagulants - administration & dosage | Adult | Factor VIII - adverse effects | Coagulants - pharmacokinetics | Hemophilia A - diagnosis | Immunoglobulin Fc Fragments - adverse effects | Immunoglobulin Fc Fragments - blood | Recombinant Fusion Proteins - administration & dosage | von Willebrand Factor - metabolism | Hemostasis - drug effects | Severity of Illness Index | Drug Administration Schedule | Treatment Outcome | Biomarkers - blood | Coagulants - blood | Hemophilia A - blood | Recombinant Fusion Proteins - blood | Models, Biological | Recombinant Fusion Proteins - pharmacokinetics | Adolescent | Factor VIII - administration & dosage | Hemorrhage - chemically induced | Infusions, Intravenous | Coagulants - adverse effects | Drug Monitoring | Hemophilia A - drug therapy | Proteins | Blood coagulation factor VIII | Analysis | Von Willebrand factor | Hemophilia | Index Medicus
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2016, Volume 75, Issue 6, pp. 1219 - 1227
ObjectivesIn the present study, we generated a new protein, recombinant human alpha-1-anti-trypsin (AAT)-IgG1 Fc fusion protein (AAT-Fc), and evaluated its... 
ALPHA-1-ANTITRYPSIN AUGMENTATION THERAPY | MONOSODIUM URATE CRYSTALS | IN-VITRO | ACUTE-PHASE PROTEIN | CYTOKINE PRODUCTION | INHIBITION | INTERLEUKIN-1-BETA | INFLAMMATION | DEFICIENT MICE | RHEUMATOLOGY | ALPHA-ANTITRYPSIN THERAPY | Arthritis, Experimental - drug therapy | Recombinant Fusion Proteins - pharmacology | Humans | Recombinant Fusion Proteins - therapeutic use | Male | Monocytes - immunology | Immunoglobulin Fc Fragments - administration & dosage | Lipopolysaccharide Receptors - analysis | Arthritis, Experimental - pathology | Dose-Response Relationship, Drug | Arthritis, Gouty - immunology | Interleukin-1beta - metabolism | Immunoglobulin Fc Fragments - therapeutic use | Interleukin 1 Receptor Antagonist Protein - biosynthesis | Recombinant Fusion Proteins - administration & dosage | Interleukin-1beta - antagonists & inhibitors | Drug Evaluation, Preclinical - methods | Mice, Inbred C57BL | Cells, Cultured | Injections, Intraperitoneal | Mice, Transgenic | Arthritis, Experimental - immunology | Gout Suppressants - administration & dosage | Monocytes - drug effects | Gout Suppressants - therapeutic use | alpha 1-Antitrypsin - administration & dosage | Arthritis, Gouty - drug therapy | alpha 1-Antitrypsin - therapeutic use | Animals | Arthritis, Gouty - pathology | Immunoglobulin Fc Fragments - pharmacology | Injections, Intra-Articular | Gout Suppressants - pharmacology | alpha 1-Antitrypsin - pharmacology | Index Medicus
Journal Article
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1338 - 1347
Journal Article